Search Results

Kenpaullone 5mg  | ≥98%

CSNpharm

Kenpaullone is an ATP-competitive inhibitor of CDK1/cyclin B (IC50 = 0.4 µM), CDK2/cyclin A (IC50 = 0.68 µM), CDK5/p25 (IC50 = 0.85 µM), lymphocyte kinase (IC50 = 0.47 µM) , and GSK-3β (C50 = 0.23 μM).

More Information Supplier Page

Kenpaullone 50mg  | ≥98%

CSNpharm

Kenpaullone is an ATP-competitive inhibitor of CDK1/cyclin B (IC50 = 0.4 µM), CDK2/cyclin A (IC50 = 0.68 µM), CDK5/p25 (IC50 = 0.85 µM), lymphocyte kinase (IC50 = 0.47 µM) , and GSK-3β (C50 = 0.23 μM).

More Information Supplier Page

Kenpaullone 10mg  | ≥98%

CSNpharm

Kenpaullone is an ATP-competitive inhibitor of CDK1/cyclin B (IC50 = 0.4 µM), CDK2/cyclin A (IC50 = 0.68 µM), CDK5/p25 (IC50 = 0.85 µM), lymphocyte kinase (IC50 = 0.47 µM) , and GSK-3β (C50 = 0.23 μM).

More Information Supplier Page

Kenpaullone 1mg  | ≥98%

CSNpharm

Kenpaullone is an ATP-competitive inhibitor of CDK1/cyclin B (IC50 = 0.4 µM), CDK2/cyclin A (IC50 = 0.68 µM), CDK5/p25 (IC50 = 0.85 µM), lymphocyte kinase (IC50 = 0.47 µM) , and GSK-3β (C50 = 0.23 μM).

More Information Supplier Page

Bekanamycin 100mg  | ≥98%

CSNpharm

Bekanamycin is an aminoglycoside antibiotic acting through irreversibly binding to the bacterial 30S ribosomal subunit, leading to interference with translational initiation complex, misreading of mRNA, thereby hampering protein synthesis.

More Information Supplier Page

Bekanamycin 25mg  | ≥98%

CSNpharm

Bekanamycin is an aminoglycoside antibiotic acting through irreversibly binding to the bacterial 30S ribosomal subunit, leading to interference with translational initiation complex, misreading of mRNA, thereby hampering protein synthesis.

More Information Supplier Page

Ivabradine HCl 10mg  | ≥98%

CSNpharm

Ivabradine HCl is the first selective sinus node I(f) channel, used for the symptomatic management of stable heart-related chest pain and heart failure not fully managed by β blockers.

More Information Supplier Page

Ketoprofen 100mg  | ≥99%

CSNpharm

Ketoprofen is a dual COX1/2 inhibitor with IC50 of 0.5 μM and 2.33 μM for human recombinant COX-1 and COX-2, respectively, and used as a nonsteroidal anti-inflammatory drug (NSAID) to treat arthritis-related inflammatory pains.

More Information Supplier Page